{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:51:39Z","timestamp":1791859899407,"version":"4.3.4"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P01-AG051459"],"award-info":[{"award-number":["P01-AG051459"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01-DK55758"],"award-info":[{"award-number":["R01-DK55758"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01-DK099110"],"award-info":[{"award-number":["R01-DK099110"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01-DK127274"],"award-info":[{"award-number":["R01-DK127274"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["RC2-DK118620"],"award-info":[{"award-number":["RC2-DK118620"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.molmet.2021.101409","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T12:19:51Z","timestamp":1638361191000},"page":"101409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3933-8626","authenticated-orcid":false,"given":"Jerry R.","family":"Colca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp E.","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmet.2021.101409_bib1","series-title":"The Seats and Causes of Diseases Investigated by Anatomy (De Sedibus et Causis Morborum per Anatomen indagata)","volume":"vol. 1","author":"Morgagni","year":"1765"},{"key":"10.1016\/j.molmet.2021.101409_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/01.hjh.0000217840.26971.b6","article-title":"The metabolic syndrome: a glance at its history","volume":"24","author":"Sarafidis","year":"2006","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.molmet.2021.101409_bib3","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.3390\/ijms21165888","article-title":"History of nonalcoholic fatty liver disease","volume":"21","author":"Lonardo","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.molmet.2021.101409_bib4","series-title":"Is type 2 diabetes an adiposity-based metabolic disease? From the origin of insulin resistance to the concept of dysfunctional adipose tissue Eating and Weight Disorders - studies on Anorexia, Bulimia and Obesity","author":"Sbraccia","year":"2021"},{"key":"10.1016\/j.molmet.2021.101409_bib5","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","article-title":"Role of insulin resistance in human disease","volume":"37","author":"Reaven","year":"1988","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2021.101409_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/diacare.14.3.173","article-title":"Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease","volume":"14","author":"DeFronzo","year":"1991","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2021.101409_bib7","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1248\/cpb.32.2267","article-title":"Studies on antidiabetic agents. IV. Synthesis and activity of the metabolites of 5-[4-(1-methyleyclohexylmethoxy)benzyl]-2,4- thiazolidinedione (ciglitazone)","volume":"32","author":"Sohda","year":"1984","journal-title":"Chemical and Pharmaceutical Bulletin"},{"key":"10.1016\/j.molmet.2021.101409_bib8","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2337\/diab.32.9.830","article-title":"Diani AR Ciglitizone, a new hypoglycemic agent. 1. Studies in ob\/ob and db\/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats","volume":"32","author":"Chang","year":"1983","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2021.101409_bib9","first-page":"37","article-title":"Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-Thiazolidinediones","volume":"40","author":"Sohda","year":"1990","journal-title":"Arzneimittel Forschung"},{"issue":"40","key":"10.1016\/j.molmet.2021.101409_bib10","first-page":"156","article-title":"Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals","volume":"1990","author":"Ikeda","year":"1990","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.molmet.2021.101409_bib11","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2337\/diacare.15.8.1075","article-title":"New oral thiazolidinedione antidiabetic agents act as insulin sensitizers","volume":"15","author":"Hofmann","year":"1992","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.molmet.2021.101409_bib12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/13543784.15.3.205","article-title":"What has prevented the expansion of insulin sensitisers?","volume":"15","author":"Colca","year":"2006","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"2","key":"10.1016\/j.molmet.2021.101409_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bcp.2006.01.002","article-title":"Insulin sensitizers may prevent metabolic inflammation","volume":"72","author":"Colca","year":"2006","journal-title":"Biochemical Pharmacology"},{"issue":"12","key":"10.1016\/j.molmet.2021.101409_bib14","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1517\/17460441.2015.1100164","article-title":"The TZD insulin sensitizer clue provides a new route into diabetes drug discovery","volume":"10","author":"Colca","year":"2015","journal-title":"Expert Opinion on Drug Discovery"},{"issue":"2021","key":"10.1016\/j.molmet.2021.101409_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00592-020-01542-4","article-title":"Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis","volume":"58","author":"Jia","year":"2021","journal-title":"Acta Diabetologica"},{"issue":"5","key":"10.1016\/j.molmet.2021.101409_bib16","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jgs.15790","article-title":"Differences in national diabetes treatment patterns and trends between older and younger adults","volume":"67","author":"Pilla","year":"2019","journal-title":"Journal of the American Geriatrics Society"},{"issue":"2","key":"10.1016\/j.molmet.2021.101409_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1479164118825376","article-title":"(2019) Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes","volume":"16","author":"DeFronzo","year":"2019","journal-title":"Diabetes and Vascular Disease Research"},{"issue":"6","key":"10.1016\/j.molmet.2021.101409_bib18","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1210\/er.2018-00141","article-title":"Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents","volume":"40","author":"Di Pino","year":"2019","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.molmet.2021.101409_bib19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"Tilg","year":"2017","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.1016\/j.molmet.2021.101409_bib20","series-title":"Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)","author":"Golabi","year":"2018"},{"key":"10.1016\/j.molmet.2021.101409_bib21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.1016\/j.molmet.2021.101409_bib22","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","author":"Loomba","year":"2013","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.1016\/j.molmet.2021.101409_bib23","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"Global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2021.101409_bib24","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.2337\/dc14-1239","article-title":"Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD:guidelines for referral in NALFD","volume":"38","author":"Bazick","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2021.101409_bib25","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.molmet.2021.101409_bib26","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmet.2021.101409_bib27","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","article-title":"Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials","volume":"73","author":"Davison","year":"2020","journal-title":"Journal of Hepatology"},{"issue":"10","key":"10.1016\/j.molmet.2021.101409_bib28","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.molmet.2021.101409_bib29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.molmet.2021.101409_bib30","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Internal Medicine"},{"issue":"9","key":"10.1016\/j.molmet.2021.101409_bib31","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/jvh.13307","article-title":"Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B","volume":"27","author":"Yip","year":"2020","journal-title":"Journal of Viral Hepatitis"},{"issue":"2","key":"10.1016\/j.molmet.2021.101409_bib32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/13543784.2020.1704731","article-title":"Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease","volume":"29","author":"Le","year":"2020","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.molmet.2021.101409_bib33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cmet.2007.12.009","article-title":"Selective versus total insulin resistance: a pathogenic paradox","volume":"7","author":"Brown","year":"2008","journal-title":"Cell Metabolism"},{"issue":"8","key":"10.1016\/j.molmet.2021.101409_bib34","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1073\/pnas.0914798107","article-title":"Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis","volume":"23","author":"Li","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.molmet.2021.101409_bib35","doi-asserted-by":"crossref","first-page":"E1709","DOI":"10.1152\/ajpendo.00444.2007","article-title":"Effect of liver fat on insulin clearance","volume":"293","author":"Kotronen","year":"2007","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"issue":"11","key":"10.1016\/j.molmet.2021.101409_bib36","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.2337\/db19-0120","article-title":"Lower insulin clearance parallels a reduced insulin sensitivity in obese youths and is associated with a decline in \u03b2-cell function over time","volume":"68","author":"Galderisi","year":"2019","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.molmet.2021.101409_bib37","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.tips.2017.04.004","article-title":"Roles of diacylglycerols and ceramides in hepatic insulin resistance","volume":"38","author":"Petersen","year":"2017","journal-title":"Trends in Pharmacological Sciences"},{"issue":"6451","key":"10.1016\/j.molmet.2021.101409_bib38","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1126\/science.aav3722","article-title":"Targeting a ceramide double bond improves insulin resistance and hepatic steatosis","volume":"365","author":"Chaurasia","year":"2019","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.molmet.2021.101409_bib39","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrd.2016.75","article-title":"Targeting adipose tissue in the treatment of obesity-associated diabetes","volume":"15","author":"Kusminski","year":"2016","journal-title":"Nature Reviews Drug Discovery"},{"issue":"5","key":"10.1016\/j.molmet.2021.101409_bib40","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cmet.2016.04.011","article-title":"Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk","author":"Stern","year":"2016","journal-title":"Cell Metabolism"},{"issue":"9","key":"10.1016\/j.molmet.2021.101409_bib41","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3390\/ijms20092358","article-title":"Adipose tissue dysfunction as determinant of obesity-associated metabolic complications review","volume":"20","author":"Longo","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"issue":"3","key":"10.1016\/j.molmet.2021.101409_bib42","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1210\/jc.2015-2860","article-title":"Evidence of beta-cell dedifferentiation in human type 2 diabetes","volume":"101","author":"Cinti","year":"2016","journal-title":"The Journal of Cinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1016\/j.molmet.2021.101409_bib43","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0026-895X(25)08890-X","article-title":"Enhancement of adipocyte differentiation by an insulin-sensitizing agent","volume":"41","author":"Kletzien","year":"1992","journal-title":"Molecular Pharmacology"},{"issue":"5","key":"10.1016\/j.molmet.2021.101409_bib44","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0006-2952(96)00345-0","article-title":"Induction of uncoupling protein in brown adipose tissue. Synergy between norepinephrine and pioglitazone, an insulin-sensitizing agent","volume":"52","author":"Foellmi-Adams","year":"1996","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.molmet.2021.101409_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/13543784.2013.839659","article-title":"Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases","volume":"23","author":"Colca","year":"2013","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.molmet.2021.101409_bib46","doi-asserted-by":"crossref","first-page":"23537","DOI":"10.1074\/jbc.M112.363960","article-title":"Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor -sparing thiazolidinedione","volume":"287","author":"Chen","year":"2012","journal-title":"Journal of Biological Chemistry"},{"issue":"22","key":"10.1016\/j.molmet.2021.101409_bib47","doi-asserted-by":"crossref","first-page":"5870","DOI":"10.1016\/j.bmc.2018.10.033","article-title":"PPAR\u03b3-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development","volume":"26","author":"Tanis","year":"2018","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.molmet.2021.101409_bib48","first-page":"1","article-title":"Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)-relationship to newly identified mitochondrial pyruvate carrier proteins","author":"Colca","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.molmet.2021.101409_bib49","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/dom.12308","article-title":"Mitochondrial target of thiazolidinediones","volume":"16","author":"Colca","year":"2014","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.molmet.2021.101409_bib50","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1073\/pnas.1303360110","article-title":"Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier","volume":"110","author":"Divakaruni","year":"2013","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.molmet.2021.101409_bib51","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/hep.29025","article-title":"Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis","volume":"65","author":"McCommis","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.molmet.2021.101409_bib52","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cmet.2015.07.028","article-title":"Loss of mitochondrial pyruvate carrier 2 in the liver leads to defects in gluconeogenesis and compensation via pyruvate-alanine cycling","volume":"22","author":"McCommis","year":"2015","journal-title":"Cell Metabolism"},{"issue":"9","key":"10.1016\/j.molmet.2021.101409_bib53","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.3390\/ijms22095047","article-title":"Epigenetics, microRNA and metabolic syndrome: a comprehensive review","volume":"22","author":"Ramzan","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"10.1016\/j.molmet.2021.101409_bib54","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.molcel.2015.10.025","article-title":"H3K4\/H3K9me3 bivalent chromatin domains targeted by lineage-specific DNA methylation pauses adipocyte differentiation","volume":"60","author":"Matsumura","year":"2015","journal-title":"Molecular Cell"},{"key":"10.1016\/j.molmet.2021.101409_bib55","doi-asserted-by":"crossref","first-page":"586179","DOI":"10.3389\/fcell.2020.586179","article-title":"NAD+ metabolism regulates preadipocyte differentiation by enhancing \u03b1-ketoglutarate-mediated histone H3K9 demethylation at the PPAR\u03b3 promoter","volume":"8","author":"Okabe","year":"2020","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10.1016\/j.molmet.2021.101409_bib56","doi-asserted-by":"crossref","first-page":"7585","DOI":"10.1038\/ncomms8585","article-title":"Obesity-induced DNA hypermethylation of the adiponectin gene mediates insulin resistance","volume":"6","author":"Kim","year":"2015","journal-title":"Nature Communications"},{"key":"10.1016\/j.molmet.2021.101409_bib57","doi-asserted-by":"crossref","first-page":"106031","DOI":"10.1016\/j.biocel.2021.106031","article-title":"Histone modifications influence the insulin-signaling genes and are related to insulin resistance in human adipocytes","volume":"137","author":"Ma\u0142odobra-Mazur","year":"2021","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"issue":"6","key":"10.1016\/j.molmet.2021.101409_bib58","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3390\/genes12060889","article-title":"PPARG hypermethylation as the first epigenetic modification in newly onset insulin resistance in human adipocytes","volume":"12","author":"Ma\u0142odobra-Mazur","year":"2021","journal-title":"Genes"},{"issue":"7","key":"10.1016\/j.molmet.2021.101409_bib59","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/13543784.2018.1494153","article-title":"MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis","volume":"27","author":"Colca","year":"2018","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.molmet.2021.101409_bib60","article-title":"Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study","author":"Harrison","year":"2019","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.molmet.2021.101409_bib61","doi-asserted-by":"crossref","first-page":"564","DOI":"10.2174\/1567205011666140616113406","article-title":"AN evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild alzheimer's disease","volume":"11","author":"Shah","year":"2014","journal-title":"Current Alzheimer Research"},{"issue":"368","key":"10.1016\/j.molmet.2021.101409_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag2210","article-title":"Mitochondrial pyruvate carrier regulates autophagy,inflammation, and neurodegeneration in experimental models of Parkinson\u2019s disease","volume":"8","author":"Ghosh","year":"2016","journal-title":"Science Translational Medicine"},{"issue":"1","key":"10.1016\/j.molmet.2021.101409_bib63","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13024-018-0260-x","article-title":"Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration","volume":"13","author":"Quansah","year":"2018","journal-title":"Molecular Neurodegeneration"},{"issue":"5","key":"10.1016\/j.molmet.2021.101409_bib64","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.dsx.2020.07.030","article-title":"SARS-CoV-2-host dynamics: increased risk of adverse outcomes of COVID-19 in obesity","volume":"14","author":"Yadav","year":"2020","journal-title":"Diabetes & Metabolic Syndrome"},{"key":"10.1016\/j.molmet.2021.101409_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.medj.2020.06.005","article-title":"When two pandemics meet: why is obesity associated with increased COVID-19 mortality?","volume":"1","author":"Lockhart","year":"2020","journal-title":"Med"},{"key":"10.1016\/j.molmet.2021.101409_bib66","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s42255-020-0237-2","article-title":"A\u00a0metabolic handbook for the COVID-19 pandemic","volume":"2","author":"Ayers","year":"2020","journal-title":"Nature Metabolism"},{"issue":"9","key":"10.1016\/j.molmet.2021.101409_bib67","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-8587(20)30238-2","article-title":"COVID-19 in people with diabetes: understanding the reasons for worse outcomes","volume":"8","author":"Apicella","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.molmet.2021.101409_bib68","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40618-020-01236-2","article-title":"Prevalence and impact of diabetes among people infected with SARS-CoV-2","volume":"43","author":"Fadini","year":"2020","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1016\/j.molmet.2021.101409_bib69","article-title":"Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1\u03b1\/glycolysis-dependent axis","volume":"17","author":"Codo","year":"2020","journal-title":"Cell Metabolism"},{"issue":"7","key":"10.1016\/j.molmet.2021.101409_bib70","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2337\/dc20-0723","article-title":"Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control?","volume":"43","author":"Sardu","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2021.101409_bib71","article-title":"SARS-CoV-2 infection induces beta cell transdifferentiation","volume":"19","author":"Tang","year":"2021","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.molmet.2021.101409_bib72","first-page":"2021","article-title":"Hyperglycemia in acute COVID-19 is characterized by adipose tissue dysfunction and insulin resistance","volume":"26","author":"Reiterer","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.molmet.2021.101409_bib73","series-title":"Multi-organ impairment in low-risk individuals with long COVID","author":"Dennis","year":"2020"},{"issue":"8","key":"10.1016\/j.molmet.2021.101409_bib74","doi-asserted-by":"crossref","first-page":"636637","DOI":"10.3389\/fmed.2021.636637","article-title":"Hepatic steatosis, rather than underlying obesity, increases the risk of infection and hospitalization for COVID-19","volume":"29","author":"Roca-Fern\u00e1ndez","year":"2021","journal-title":"Frontiers of Medicine"},{"issue":"7","key":"10.1016\/j.molmet.2021.101409_bib75","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/oby.22856","article-title":"The role of adipocytes and adipocyte-like cells in the severity of COVID-19 infections","volume":"28","author":"Kruglikov","year":"2020","journal-title":"Obesity"},{"issue":"3","key":"10.1016\/j.molmet.2021.101409_bib76","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1086\/653842","article-title":"Association between H1N1 infection severity and obesity-adiponectin as a potential etiologic factor","volume":"202","author":"Tsatsanis","year":"2010","journal-title":"The Journal of Infectious Diseases"},{"issue":"6","key":"10.1016\/j.molmet.2021.101409_bib77","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41366-021-00804-7","article-title":"Metabolic dysfunction and immunometabolism in COVID-19 pathophysiology and therapeutics","volume":"45","author":"Batabyal","year":"2021","journal-title":"International Journal of Obesity"},{"issue":"5","key":"10.1016\/j.molmet.2021.101409_bib78","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.molmet.2021.101409_bib79","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","article-title":"Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19","volume":"26","author":"Liao","year":"2020","journal-title":"Nature Medicine"},{"key":"10.1016\/j.molmet.2021.101409_bib80","doi-asserted-by":"crossref","first-page":"101611","DOI":"10.1016\/j.isci.2020.101611","article-title":"PPAR\u03b3 cistrome repression during activation of lung monocyte-macrophages in severe COVID-19","volume":"23","author":"Desterke","year":"2020","journal-title":"iScience"},{"issue":"9","key":"10.1016\/j.molmet.2021.101409_bib81","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00030-19","article-title":"PPAR-\u03b3 in macrophages limits pulmonary inflammation and promotes host recovery following respiratory viral infection","volume":"93","author":"Huang","year":"2019","journal-title":"Journal of Virology"},{"issue":"4","key":"10.1016\/j.molmet.2021.101409_bib82","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/vim.2019.0016","article-title":"Targeting peroxisome proliferator-activated receptor-gamma decreases host mortality after influenza infection in obese mice","volume":"32","author":"Huang","year":"2019","journal-title":"Viral Immunology"},{"issue":"10","key":"10.1016\/j.molmet.2021.101409_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223430","article-title":"Macrophage PPAR-\u03b3 suppresses long-term lung fibrotic sequelae following acute influenza infection","volume":"14","author":"Huang","year":"2019","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.molmet.2021.101409_bib84","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2337\/db19-0640","article-title":"Pharmacologic PPAR-\u03b3 activation reprograms bone marrow macrophages and partially rescues HSPC mobilization in human and murine diabetes","volume":"69","author":"Tedesco","year":"2020","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.molmet.2021.101409_bib85","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/s41467-021-21461-4","article-title":"Fructose reprogrammes glutamine-dependent oxidative metabolism to support LPS-induced inflammation","volume":"12","author":"Jones","year":"2021","journal-title":"Nature Communications"},{"issue":"5","key":"10.1016\/j.molmet.2021.101409_bib86","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","article-title":"Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial","volume":"7","author":"Lean","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.molmet.2021.101409_bib87","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S2213-8587(19)30076-2","article-title":"Understanding the mechanisms of reversal of type 2 diabetes","volume":"7","author":"Taylor","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.molmet.2021.101409_bib88","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3390\/jcm10061326","article-title":"Ectopic fat accumulation in pancreas and heart","volume":"10","author":"Kozawa","year":"2021","journal-title":"Journal of Clinical Medicine"},{"issue":"1","key":"10.1016\/j.molmet.2021.101409_bib89","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.soard.2020.10.026","article-title":"Association of prior metabolic and bariatric surgery with severity of coronavirus disease 2019 (COVID-19) in patients with obesity","volume":"17","author":"Aminian","year":"2021","journal-title":"Surgery for Obesity and Related Diseases"},{"issue":"1","key":"10.1016\/j.molmet.2021.101409_bib90","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/nyas.14211","article-title":"Incretins in obesity and diabetes","volume":"1461","author":"Chia","year":"2020","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.molmet.2021.101409_bib91","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijcard.2011.09.039","article-title":"Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population","volume":"162","author":"Doehner","year":"2012","journal-title":"International Journal of Cardiology"},{"issue":"2","key":"10.1016\/j.molmet.2021.101409_bib92","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.cmet.2018.09.022","article-title":"Profound perturbation of the metabolome in obesity is associated with health risk","volume":"29","author":"Cirulli","year":"2019","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.molmet.2021.101409_bib93","doi-asserted-by":"crossref","first-page":"100807","DOI":"10.1016\/j.jbc.2021.100807","article-title":"Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide","volume":"19","author":"Kamm","year":"2021","journal-title":"Journal of Biological Chemistry"},{"issue":"12","key":"10.1016\/j.molmet.2021.101409_bib94","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.3390\/nu12123737","article-title":"Additive effects of omega-3 fatty acids and thiazolidinediones in mice fed a high-fat diet: triacylglycerol\/fatty acid cycling in adipose tissue","volume":"12","author":"Bardova","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.molmet.2021.101409_bib95","series-title":"Diabetes, drug treatment and mortality in COVID-19: a multinational retrospective cohort study diabetes. 2021 sep 27;db210385","author":"Nyland","year":"2021"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877821002672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877821002672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:26:21Z","timestamp":1761956781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877821002672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":95,"alternative-id":["S2212877821002672"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2021.101409","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2021.101409","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"101409"}}